TLDR COVID-19 vaccination may be linked to MIS-C in children, highlighting the need for quick diagnosis and treatment.
This case report and literature review discuss a 6-year-old girl who developed severe multisystem inflammatory syndrome in children (MIS-C) 30 days after receiving her second dose of the COVID-19 vaccine, despite no prior detected SARS-CoV-2 infection. She presented with fever, abdominal pain, rash, and other symptoms, and was diagnosed with MIS-C through positive anti-SARS-CoV-2 antibodies. Treatment with intravenous immunoglobulins and methylprednisone led to initial improvement, but she later developed pancreatitis and severe neurological symptoms, which resolved after 2 months. She also experienced transient hair loss (telogen effluvium) 3 months post-symptom onset. After 12 months, she showed no symptomatic sequelae. The case suggests a potential link between COVID-19 vaccination and MIS-C in young children and underscores the importance of prompt diagnosis and treatment.
12 citations,
July 2022 in “Journal of Cosmetic Dermatology” COVID-19 patients may experience temporary hair loss, mainly in women, which is likely reversible.
7 citations,
May 2022 in “The Journal of Dermatology” Hair loss is a frequent long-term effect of COVID-19, and oral minoxidil is the most common effective treatment.
2 citations,
February 2021 in “The Pediatric Infectious Disease Journal” Hair loss may be a delayed side effect of Multisystem Inflammatory Syndrome in children after COVID-19.
28 citations,
January 2021 in “Skin appendage disorders” COVID-19 may cause early hair loss similar to classic temporary hair loss, with further research needed.
58 citations,
November 2020 in “International Journal of Dermatology” COVID-19 may cause a temporary hair loss condition called telogen effluvium in some patients after recovery.
24 citations,
January 2015 in “Current problems in dermatology” The document concludes that accurate diagnosis of hair loss in children is crucial due to limited treatment options and the condition's psychological impact.
2 citations,
February 2021 in “The Pediatric Infectious Disease Journal” Hair loss may be a delayed side effect of Multisystem Inflammatory Syndrome in children after COVID-19.
January 2018 in “Przegla̧d dermatologiczny” The Polish Dermatological Society recommends personalized treatment for cutaneous lupus, including lifestyle changes, medications, and monitoring, with specific drugs for severe cases.
34 citations,
June 2014 in “The BMJ” Pregnancy can change skin disease severity, with some conditions improving and others worsening, and treatment should balance benefits and fetal safety.
273 citations,
May 2017 in “The Lancet” Some drugs can cause rare but potentially deadly skin reactions, and early treatment and avoiding the drug again are key.
9 citations,
August 2002 in “Current Opinion in Pediatrics” An 18-year-old girl with pemphigus vulgaris needed strong medication and careful treatment due to ineffective initial therapies and side effects.
